EGFR and pachyonychia congenita: Furthermore, an ACNPs therapy based on cetuximab, an anti-EGFR conjugated with an NP encapsulating the topoisomerase inhibitor camptothecin, showed a reduction in cancer growth in PC cell lines (McDaid et al., 2019).